Home-cooked Italian Seafood Dinner
Sauteed Cuttlefish with Tomato
Risotto with White Baits and Broad Beans
250 g (8 oz) fresh scallops
4 tablespoons red curry paste
2 tablespoons vegetable oil
2 cloves garlic, finely chopped
2 fresh red chilies, finely sliced
2 tablespoons fish sauce
1 tablespoon sugar
1 cup fresh basil leaves, divided
Source: Thai Cooking Class
Don’t fall for products claiming to cure autism, the U.S. Food and Drug Administration warns.
There’s no cure for the neurodevelopmental disorder, the agency said. Yet bogus “cures” and therapies abound — from toxin removal to raw camel milk.
Some of these fraudulent treatments could be harmful, and should be avoided, the agency said Wednesday.
Among them: chelation therapies, hyperbaric oxygen therapy and detoxifying clay baths.
Autism spectrum disorder affects about 1 in 68 children in the United States, boys far more often than girls.
“Autism varies widely in severity and symptoms. Existing autism therapies and interventions are designed to address specific symptoms and can bring about improvement,” FDA pediatrician Dr. Amy Taylor said in an agency news release.
Children with an autism spectrum disorder have difficulties with social interaction and communication. They often exhibit repetitive behaviors and have narrow, obsessive interests, according to the U.S. National Institutes of Health.
Some FDA-approved drugs can help control autism symptoms. For example, antipsychotics such as risperidone (Risperdal) and aripiprazole (Abilify) are prescribed to children to treat irritability associated with autism.
But, there has been a long history of failed autism treatments and fads. These include the following:
Chelation therapies claim to cleanse the body of toxic chemicals and heavy metals. They come in spray form, suppositories, capsules, liquid drops and clay baths.
FDA-approved chelating agents are available by prescription only. They’re approved for the treatment of lead poisoning and iron overload, but not the treatment or cure of autism. These products should only be used under professional supervision because they can deplete the body of important minerals and lead to serious and life-threatening problems, the FDA said.
Hyperbaric oxygen therapy, another unproven treatment for autism, involves breathing oxygen in a pressurized chamber. It has FDA approval only for certain medical uses, such as treating decompression sickness suffered by scuba divers.
Detoxifying clay baths are falsely marketed as providing “dramatic improvement” in autism symptoms, the FDA said. The products, mixed in bath water, are said to draw out chemical toxins, pollutants and heavy metals from the body.
Raw camel milk and essential oils are among other products sold as autism treatments. But, they have not been proven safe or effective, according to the FDA.
Jason Humbert, a regulatory operations officer in the FDA’s Office of Regulatory Affairs, said, “Be suspicious of products that claim to treat a wide range of diseases.”
Humbert cited several ways consumers can identify false or misleading claims about products that purport to cure or treat autism.
Understand that personal testimonials are no substitute for scientific evidence, he said.
Also, few diseases or conditions can be treated quickly, so be wary of any therapy claiming to be a “quick fix,” he added.
Similarly, “miracle cures” that boast of scientific breakthroughs or secret ingredients are likely a hoax, Humbert said.
Before using any little-known therapy or product that claims to treat or cure autism, check with your health care professional, the FDA said.
As a national leader in innovative ophthalmology treatments that prevent blindness the University of Southern California (USC) Roski Eye Institute became the first team in Los Angeles county to implant the XEN® gel stent in glaucoma patients on March 9, 2017. The XEN gel stent was approved by the U.S. Food and Drug Administration in November 2016. It became available for implantation in patients nationwide three weeks ago.
The half-dozen glaucoma stent implant procedures for Los Angeles-area patients were performed by USC Roski Eye Institute ophthalmologists Alena Reznik, MD, and Sahar Bedrood, MD, PhD. The XEN gel stent is made of non-degradable soft collagen-derived gelatin. It is a minimally invasive, outpatient surgical option for glaucoma patients whose intra-ocular pressure (IOP) cannot be managed by medications or laser treatment. It allows glaucoma patients to avoid more invasive surgical procedures such as trabeculectomy and tube shunt surgeries. The XEN gel stent lets eye fluid drain from inside the eye to under the clear skin of the eye on the outside, reducing elevated eye pressure that can eventually lead to blindness if not alleviated.
“The XEN gel stent is a unique device that conforms to the ocular tissue and is successful at fluid drainage and reducing eye pressure while also being extremely comfortable for the patient,” said Reznik, an assistant professor of clinical ophthalmology. “Since it is a less invasive procedure than other traditional glaucoma surgical options, there are less side effects and the patients recover more quickly.”
Reznik added that USC Roski Eye Institute was proud to be the first in Los Angeles to implant the XEN device since the USC Roski Eye Institute director Rohit Varma, MD, MPH, had worked with AqueSys Inc. to design the device and analyze the outcomes data over several years of clinical trials conducted in refractory glaucoma patients.
“The XEN device is a game changer for patients with primary open-angle glaucoma, pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy,” said Varma, who also serves as dean of Keck School of Medicine of USC. “In addition to offering a minimally invasive option for glaucoma patients that was successful in reducing eye pressure, our analysis also showed it helped reduce the study participant’s medications.”
Varma’s data analysis during clinical trials showed that one year after the implant, eye pressure was reduced by 44 percent from baseline and IOP medications, including eye drops, were reduced by 65 percent.
“It’s gratifying to see the XEN come full circle – we’re grateful to Dr. Varma, who was a valued advisor during several years of development and study of the device. Today, we celebrate the first patients in L.A. who received the XEN from glaucoma experts Dr. Reznik and Dr. Bedrood at USC,” said Roger Kash, director of professional education at AqueSys Inc.
More than 3 million Americans have glaucoma, which is defined as a disease that damages the optic nerve of the eye. It most often occurs after age 40 and there is increased risk for glaucoma after age 60, but it can also be diagnosed in infants and children. Part of the difficulty in diagnosing glaucoma is that there are few, if any, warning signs. Risk factors include increased age, family history and medical conditions such as diabetes, heart disease and high blood pressure. African Americans and Latinos have a higher risk of glaucoma than non-Hispanic whites.
“Glaucoma does not have to lead to blindness,” said Varma. “The disease progresses slowly, usually without any symptoms, so an annual dilated eye exam for early detection and treatment, especially after the age of 50, is essential to prevent blindness.”
Source: USC Roski Eye Institue